If youâre interested in adding some ASX 200 blue chip shares to your portfolio this month, then the three listed below could be worth considering.
These ASX 200 shares have all been named as buys recently. Hereâs what you need to know about them:
Cochlear Limited (ASX: COH)
The first ASX 200 blue chip share to look at is Cochlear. It is one of the worldâs leading hearing solutions companies with a portfolio of industry-leading cochlear implant devices.
But management is never one to rest on its laurels. Each year, the company spends heavily on its research and development activities in order to stay ahead of the pack.
Goldman Sachs is a fan of Cochlear. It believes it is well-placed to outperform expectations in FY 2023. As a result, the broker has put a buy rating and $265.00 price target on its shares.
Goodman Group (ASX: GMG)
Another ASX 200 blue chip share that has been named as a buy is Goodman Group. It is one of the worldâs leading integrated commercial and industrial property companies.
Goodman has been growing at a consistently strong rate for years thanks to its expertly constructed portfolio that gives it exposure to key growth markets such as ecommerce and logistics.
The good news is that the team at Citi appears to believe this run can continue. Its analysts are forecasting double-digit earnings per share growth out until at least FY 2025.
Itâs no surprise then to learn that Citi has a buy rating on its shares with a $24.00 price target.
ResMed Inc. (ASX: RMD)
A final ASX 200 blue chip share to consider buying is ResMed. Like the others, it is an industry leader, this time in the sleep treatment market.
Also like the others, ResMed has been growing at a solid rate for years and has been tipped to continue doing so for the foreseeable future.
Morgans is among the brokers expecting big things from the company in the coming years. As a result, it has ResMed on its best ideas list with an add rating and $37.80 price target.
The post Here are 3 ASX 200 blue chip shares that analysts love appeared first on The Motley Fool Australia.
FREE Investing Guide for Beginners
Despite what some people may say – we believe investing in shares doesn’t have to be overwhelming or complicated…
For over a decade, we’ve been helping everyday Aussies get started on their journey.
And to help even more people cut through some of the confusion “experts’” seem to want to perpetuate – we’ve created a brand-new “how to” guide.
Yes, Claim my FREE copy!
*Returns as of April 3 2023
(function() {
function setButtonColorDefaults(param, property, defaultValue) {
if( !param || !param.includes(‘#’)) {
var button = document.getElementsByClassName(“pitch-snippet”)[0].getElementsByClassName(“pitch-button”)[0];
button.style[property] = defaultValue;
}
}
setButtonColorDefaults(“#0095C8”, ‘background’, ‘#5FA85D’);
setButtonColorDefaults(“#0095C8”, ‘border-color’, ‘#43A24A’);
setButtonColorDefaults(“#fff”, ‘color’, ‘#fff’);
})()
More reading
- 2 ASX 200 stocks surging ahead following guidance upgrades
- Here are 2 outstanding ASX 200 growth shares brokers rate as buys
- On my ASX watchlist: Is ResMed borrowing Apple’s multi-billion-dollar playbook?
- Brokers name 3 ASX 200 blue chip shares to buy
- Leading brokers name 3 ASX shares to buy today
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Cochlear and Goodman Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/IFexC8g
Stock Pick 